FDA Adverse Event Injury Summary report: N

BIFURCATED GORE-TEX® STRETCH VASCULAR GRAFT

MDR report key: 8319451 · Received February 8, 2019

Report

Report Number
2017233-2019-00070
Event Type
Injury
Date Received
February 8, 2019
Date of Event
May 25, 2018
Report Date
May 13, 2019
Manufacturer
W.L. GORE & ASSOCIATES
Product Code
DSY
UDI-DI
00733132611829
PMA / PMN Number
K904282
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FR
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

ADDITIONAL INFORMATION WAS ENTERED FOR THE FOLLOWING: RESULT CODE 213 WAS ADDED, REFER TO EXPLANT EVALUATION SUMMARY. UPDATED PATIENT CODE 2; DEVICE CODE 2; RESULT CODE 2 AND CONCLUSION CODE 2. THE BIFURCATED GORE-TEX® STRETCH VASCULAR GRAFT WAS RETURNED TO GEPROVAS, INDEPENDENT LABORATORY, FOR INVESTIGATION. THE SCOPE AND RESULTS OF THE INVESTIGATION WERE SUMMARIZED AND A REPORT WAS SUBMITTED TO W. L. GORE & ASSOCIATES. AN EXPLANT INVESTIGATOR (EI) AT W. L. GORE & ASSOCIATES REVIEWED THE REPORT. THE FOLLOWING IS A SUMMARY OF THE EI OBSERVATIONS: THE DEVICE FRAGMENT WAS GENERALLY DEVOID OF TISSUE ON THE ABLUMINAL SURFACES, EXCEPT FOR A RED/BROWN TISSUE AT THE DISTAL EXTREMITIES OF SB1601D. A MINIMAL AMOUNT OF DARK RED/BROWN TISSUE WAS VISIBLE ON THE LUMINAL SURFACE OF SB1601D. LUMEN PATENCY FOR THE DEVICE COULD NOT BE DETERMINED FROM THE INFORMATION PROVIDED. THE BRANCH OF BIFURCATED GRAFT WAS TRANSECTED AND REMOVED BELOW THE AREA OF BIFURCATION. BOTH POLES OF THE FRAGMENT WERE TRANSECTED. ONE POLE WAS BEVELED AND CONTAINED BLUE RUNNING SUTURE, INDICATING AN ANASTOMOTIC SITE. THE OTHER POLE HAD SERRATION MARKS ON THE ALBUMEN SURFACE. IN AREAS, THE FRAGMENT APPEARED FLATTENED AND KINKED. ONE FRAGMENT CONTAINED TWO ATTACHED DEVICE FRAGMENTS: THE BIFURCATED GORE-TEX® STRETCH VASCULAR GRAFT (SB1601D) MAIN BODY AND BRANCH FRAGMENT: BELOW THE AREA OF BIFURCATION, ONE BRANCH HAD BEEN REMOVED AND ONE BRANCH WAS STILL ATTACHED. THE ATTACHED BRANCH WAS KINKED IN THE MIDDLE (LIKELY DUE TO TRANSPORT IN AN UNDERSIZED CONTAINER) AND HAD SERRATION MARKS NEAR THE DISTAL POLE. THE DISTAL POLE WAS TRANSECTED, BEVELED AND CONTAINED BLUE RUNNING SUTURE, INDICATING AN ANASTOMOTIC SITE. THE FRAGMENT LUMEN WAS OVULAR AND FLAT. THE PROPATEN® VASCULAR GRAFT FRAGMENT (H050060) WAS ATTACHED TO THE PROXIMAL PORTION OF SB1601D IN AN END TO SIDE CONFIGURATION, ABOVE THE AREA OF BIFURCATION, WITH WHITE RUNNING SUTURE. THE DISTAL POLE WAS TRANSECTED, FLATTENED AND OVULAR IN SHAPE. FROM GROSS IMAGES ALL MATERIAL DISRUPTIONS (I.E., MATERIAL TRANSECTIONS AND SERRATION MARKS), APPEAR TO BE CONSISTENT WITH CUTTING BY SHARP SURGICAL INSTRUMENTS (I.E., SCALPEL OR SCISSORS) AND CLAMPING BY A SURGICAL INSTRUMENT (I.E., FORCEPS OR SURGICAL CLAMP), LIKELY USED DURING A SURGICAL PROCEDURE. AS ADDITIONAL INFORMATION REVEALED THAT ALSO A GORE® PROPATEN® VASCULAR GRAFT WAS INVOLVED IN THE MEDICAL DEVICE INCIDENT, THE SECOND GORE DEVICE WILL BE ALSO REPORTED TO THE FDA UNDER MFR REPORT #2017233-2019-00015.

Additional Manufacturer Narrative · 1

AS ADDITIONAL INFORMATION REVEALED THAT ALSO A GORE® PROPATEN® VASCULAR GRAFT WAS INVOLVED IN THE MEDICAL DEVICE INCIDENT, THE SECOND GORE DEVICE WILL BE ALSO REPORTED TO THE FDA UNDER MFR REPORT #2017233-2019-00015.

Description of Event or Problem · 1

ON AN UNKNOWN DATE A BIFURCATED GORE-TEX® STRETCH VASCULAR GRAFT WAS IMPLANTED IN ORDER TO TREAT AN UNKNOWN DISEASE. ON (B)(6) 2016, A GORE® PROPATEN® VASCULAR GRAFT WAS IMPLANTED IN A (B)(6) MALE PATIENT AS AN EXTENSION OF THE PREVIOUSLY IMPLANTED BIFURCATED GORE-TEX® STRETCH VASCULAR GRAFT IN ORDER TO TREAT A CRITICAL ISCHEMIA. ON (B)(6) 2018, AFTER ABOUT TWO YEARS, THE BIFURCATED GORE-TEX® STRETCH VASCULAR GRAFT AS WELL AS THE GORE® PROPATEN® VASCULAR GRAFT WAS EXPLANTED DUE TO A FALSE ANASTOMOTIC ANEURYSM AND AN INFECTION TO STAPHYLOCOCCUS AUREUS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
114395 BIFURCATED GORE-TEX® STRETCH VASCULAR GRAFT PROSTHESIS, VASCULAR GRAFT DSY W.L. GORE & ASSOCIATES 13995039 00733132611829

Patients

Seq Age Sex Outcome Treatment
1 50 YR Required Intervention